Enterofuril - instructions for use, dose, side effects, contraindications

Excipients: sucrose 1000.0 mg, sodium hydroxide 2.0 mg, methyl parahydroxybenzoate 5.0 mg, ethanol 96% 0.05 ml, carbomer 10.5 mg, citric acid 0.75 mg, flavoring banana 10.00 mg, water up to 5.0 ml .

Description:Suspension yellow with the smell of a banana.

Pharmacotherapeutic group:Antimicrobial agent, nitrofuran.

ATX: & nbsp

A.07.A.X.03 Nifuroxazide

Pharmacodynamics:A broad-spectrum antimicrobial agent, a derivative of 5-nitrofuran.

It is assumed that the antimicrobial activity of nifuroxazide is caused by the presence in its composition NO₂-group, which causes inhibition of dehydrogenase activity and disrupts the synthesis of proteins in pathogenic bacteria.

Active against gram-positive microorganisms (Streptococcus pyogenes, Staphylococcus pyogenes, Clostridium), Gram-negative enterobacteria (Escherichia coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter spp., Vibrio cholerae, Campilobacter, Edwarsiella, Citrobacter, Yersinia).

Nifuroxazide has no effect on saprophyte flora, does not disturb the balance of normal intestinal flora. With acute bacterial diarrhea, eubiosis of the intestine is restored. When infected with enterotrophic viruses prevents the development of bacterial superinfection.

Pharmacokinetics:

After oral administration nifuroxazide practically not absorbed from the digestive tract, and its antibacterial action exerts exclusively in lumen of the intestine. Completely eliminated through the gastrointestinal tract. Speed Elimination depends both on the dose of the drug and on the intestinal motility.

Indications:

- Diarrhea of bacterial genesis;

- Chronic lesions of the gastrointestinal tract of bacterial etiology, accompanied by dyspeptic phenomena

Contraindications:

- Hypersensitivity to derivatives of nitrofuran or other components of the drug;

- Intolerance to fructose;

- Syndrome of glucose-galactose malabsorption or insufficiency of sucrose and isomaltase;

- The period of neonatal (up to 1 month), prematurity.

Pregnancy and lactation:

The use of Enterofuril® during pregnancy is possible only in cases when the expected benefit of therapy for the mother exceeds the potential risk to the fetus. Enterofuril® is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, however, the use of the drug during lactation is possible only on strict indications,at the same time, the issue of stopping breastfeeding should be addressed.

Dosing and Administration:

It is applied inside.

For dispensing a dosage spoon with a volume of 5 ml, having a calibration of 2.5 ml is used.

Before use, the suspension should be shaken well.

Children 1-6 months: 2.5 ml 2 - 3 times a day (with an interval of 8 to 12 hours).

Children from 7 months to 2 years: 2.5 ml 4 times a day (with an interval of 8 hours).

Children from 3 to 7 years: 5 ml 3 times a day (with an interval of 8 hours).

Children older than 7 years and adults: 5 ml 3-4 times a day (with an interval of 6-8 hours).

Nifuroxazide therapy should not last more than 7 days.

Side effects:Allergic reactions, nausea, vomiting.

Overdose:The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Symptoms of overdose are not known. In case of exceeding the dose, gastric lavage and symptomatic treatment are recommended.

Interaction:

There is no evidence that nifuroxazide interacts with other drugs.

Special instructions:

When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be performed in accordance withpatient's condition and intensity of diarrhea.

It is forbidden to use alcohol during therapy with nifuroxazide.

Before the suspension is prescribed to infants, it is necessary to exclude from them an inborn deficiency of enzymes that break down sucrose.

Effect on the ability to drive transp. cf. and fur:The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.

Form release / dosage:Suspension for oral administration 200 mg / 5 ml.

Packaging:For 90 ml in a bottle of dark glass, sealed with an aluminum lid with a control of the first opening, or a screwed plastic lid, equipped with a child protection mechanism, sealant and the first opening control. One bottle with instructions for use and a measuring spoon is placed in a cardboard box.

Storage conditions:

At a temperature of 15 ° to 30 ° C.

Keep out of the reach of children.

The vial should not be stored more than 14 days.

Shelf life:

3 years

Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:П N014624 / 02

Date of registration:06.11.2008

The owner of the registration certificate:Boznalek, AOBoznalek, AO Bosnia and Herzegovina

Manufacturer: & nbsp

BOSNALIJEK, d.d. Bosnia and Herzegovina

Representation: & nbspBOSNALEK AO BOSNALEK AO Bosnia and Herzegovina

Information update date: & nbsp30.07.2015

Illustrated instructions

Instructions

Enterofuryl® (Enterofuryl®)